Loading...

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors. Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Nucleic Acid Ther
Main Authors: Sutherland, Jessica E., Hettinger, Julia L., Chan, Amy, Gilbert, Jason, Warner, Garvin L., Davis, Wendell P.
Format: Artigo
Sprog:Inglês
Udgivet: Mary Ann Liebert, Inc., publishers 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6987735/
https://ncbi.nlm.nih.gov/pubmed/31821125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/nat.2019.0796
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!